Diagnosis and treatment of SAD related disorders

Abstract

The present invention relates to SAD polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for SAD related diseases or conditions characterized by an abnormal interaction between a SAD polypeptide and a SAD binding partner.

What is claimed is:  
     
         1 . An isolated, enriched or purified nucleic acid molecule encoding a SAD polypeptide.  
     
     
         2 . The nucleic acid molecule of  claim 1 , wherein said nucleic acid molecule comprises a nucleotide sequence that 
 (a) encodes a polypeptide having the full length amino acid sequence set forth in SEQ ID NO: 2;    (b) is the complement of the nucleotide sequence of (a);    (c) hybridizes under highly stringent conditions to the nucleotide molecule of (a) and encodes a naturally occurring SAD polypeptide;    (d) encodes a SAD polypeptide having the full length amino acid sequence of the sequence set forth in SEQ ID NO: 2, except that it lacks one or more of the following segments of amino acid residues: 1-55, 56-109, 120-212, 230-480, 481-488 of SEQ ID NO: 2;    (e) is the complement of the nucleotide sequence of (d);    (f) encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 2 from amino acid residues 1-55, 56-109, 120-212, 230-480, 481-488 of SEQ ID NO: 2;    (g) is the complement of the nucleotide sequence of (f);    (h) encodes a polypeptide having the full length amino acid sequence set forth in SEQ ID NO: 2, except that it lacks one or more of the domains selected from the group consisting of an N-terminal domain, an SH2 domain, an SH3 domain, and a catalytic domain; or    (i) is the complement of the nucleotide sequence of (h).    
     
     
         3 . The nucleic acid molecule of  claim 1 , wherein said nucleic acid molecule is isolated, enriched, or purified from a mammal.  
     
     
         4 . The nucleic acid molecule of  claim 3 , wherein said mammal is a human.  
     
     
         5 . The nucleic acid molecule of  claim 1 , further comprising a vector or promoter effective to initiate transcription in a host cell.  
     
     
         6 . A nucleic acid probe for the detection of nucleic acid encoding a SAD polypeptide in a sample.  
     
     
         7 . The probe of  claim 6  wherein said polypeptide comprises at least 6 contiguous amino acids of the amino acid sequence shown in SEQ ID NO: 2.  
     
     
         8 . A nucleic acid molecule comprising one or more regions that encode a SAD polypeptide or a SAD domain polypeptide, wherein said SAD polypeptide or said SAD domain polypeptide is fused to a non-SAD polypeptide.  
     
     
         9 . A recombinant cell comprising a nucleic acid molecule encoding either 
 (a) a SAD polypeptide;    (b) a SAD domain polypeptide; or    (c) a SAD polypeptide or SAD domain polypeptide fused to a non-SAD polypeptide.    
     
     
         10 . An isolated, enriched or purified SAD polypeptide.  
     
     
         11 . The polypeptide of  claim 10 , wherein said polypeptide is a fragment of the protein encoded by the full length amino acid sequence set forth in SEQ ID NO: 2.  
     
     
         12 . The polypeptide of  claim 10 , wherein said polypeptide comprises an amino acid sequence having 
 (a) the full length amino acid sequence set forth in SEQ ID NO: 2;    (b) the full length amino acid sequence of the sequence set forth in SEQ ID NO: 2, except that it lacks one or more of the following segments of amino acid residues: 1-55, 56-109, 120-212, 230-480, 481-488 of SEQ ID NO: 2;    (c) the amino acid sequence set forth in SEQ ID NO: 2 from amino acid residues 1-55, 56-109, 120-212, 230-480, 481-488 of SEQ ID NO: 2; or    (d) the full length amino acid sequence set forth in SEQ ID NO: 2 except that it lacks one or more of the domains selected from the group consisting of an N-terminal domain, an SH2 domain, an SH3 domain, and a catalytic domain.    
     
     
         13 . An antibody or antibody fragment having specific binding affinity to a SAD polypeptide or a SAD domain polypeptide.  
     
     
         14 . A hybridoma which produces an antibody having specific binding affinity to a SAD polypeptide.  
     
     
         15 . A method for identifying a substance capable of modulating SAD activity comprising the steps of: 
 (a) contacting a SAD polypeptide with a test substance, and    (b) determining whether said substance alters the activity of said polypeptide.    
     
     
         16 . A method for identifying a substance capable of modulating SAD activity in a cell comprising the steps of: 
 (a) expressing a SAD polypeptide in a cell,    (b) adding a test substance to said cells, and    (c) monitoring a change in cell phenotype, cell proliferation, cell differentiation, SAD catalytic activity, or the interaction between a SAD polypeptide and a natural binding partner.    
     
     
         17 . A method of preventing or treating an abnormal condition by administering to a patient in need of such treatment a compound that modulates the function of a SAD polypeptide.  
     
     
         18 . The method of  claim 17 , wherein said abnormal condition involves an abnormality in SAD signal transduction pathway.  
     
     
         19 . The method of  claim 18 , wherein said abnormal condition is cancer.  
     
     
         20 . The method of  claim 17 , wherein said compound modulates the function of a SAD polypeptide in vitro.  
     
     
         21 . A kit, comprising the compound of  claim 17  and a protocol for the use of said compound.  
     
     
         22 . The kit of  claim 21 , wherein said protocol is approved by the Food and Drug Administration.